Cambridge biopharmaceutical company Acceleron pledges $25,000 in support of YW Boston and the advancement of racial equity


Boston, MA — Local biopharmaceutical company Acceleron Pharma joins an increasing number of STEM companies around the country that are strengthening their commitment to social responsibility and taking action to address some of today’s most pressing systemic inequities. As part of this commitment, Acceleron is partnering with YW Boston to improve internal diversity, equity, and inclusion, as well as raise critical funds that will support YW Boston’s work within communities around the Greater Boston area. In addition to a generous corporate gift of $25,000, Acceleron employees will be able to increase the impact of their personal gift to YW Boston through an employee matching gifts program.


“It is imperative for all sectors and industries to become involved in the pursuit of social justice and racial equity for our city, and for the country as a whole,” said YW Boston President and CEO Beth Chandler. “Nonprofits cannot do this work alone. We need organizations to consider how they might be reinforcing systemic inequities and take the necessary steps to ensure more equitable outcomes for their employees, stakeholders, and the broader community.”


“We are grateful for Acceleron’s support of YW Boston’s important mission to eliminate racism, empower women, and promote peace, justice, freedom, and dignity for all,” Beth continued. “As we face the compounded crises of racism and a global pandemic, it’s crucial for organizations to use their power and resources to invest in a different future, one with more equitable outcomes for women, people of color, and women of color in particular. We look forward to working together with Acceleron to make an impact in the City of Boston and beyond.”



About YW Boston

As the first YWCA in the nation, YW Boston has been at the forefront of advancing equity for over 150 years. Through our DE&I services—InclusionBoston and LeadBoston—as well as our advocacy work and F.Y.R.E. Initiative, we help individuals and organizations change policies, practices, attitudes, and behaviors with a goal of creating more inclusive environments where women, people of color, and especially women of color can succeed.

As part of that work, we are helping organizations prioritize Diversity, Equity & Inclusion and become socially connected while staying physically distant. During this time, YW Boston is providing organizations with digital workshops and resources to help them better understand the challenges faced by their employees. For more information, please contact Sheera Bornstein at


About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.

Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States and Europe for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial.



For Immediate Release:
Coralys Negretti
Director of Marketing & Communications